Published in Cancer Res on September 15, 2005
The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell (2007) 2.10
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res (2010) 2.06
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett (2013) 1.74
Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. J Cancer Res Clin Oncol (2014) 1.49
Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev (2009) 1.48
Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res (2010) 1.47
Structural basis of PP2A inhibition by small t antigen. PLoS Biol (2007) 1.32
Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell (2010) 1.29
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res (2009) 1.27
Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancer. Virology (2008) 1.20
A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A. Oncogene (2010) 1.09
Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol (2011) 1.08
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer (2006) 1.03
Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia (2011) 1.03
PP2A-Mediated Anticancer Therapy. Gastroenterol Res Pract (2013) 1.01
Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice. Mol Cell Biol (2011) 1.00
Functions of B56-containing PP2As in major developmental and cancer signaling pathways. Life Sci (2010) 0.99
PP2A:B56{epsilon}, a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development. J Biol Chem (2010) 0.96
Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways. Cell Cycle (2012) 0.96
Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br J Cancer (2013) 0.95
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci (2011) 0.94
A novel Epac-Rap-PP2A signaling module controls cAMP-dependent Akt regulation. J Biol Chem (2008) 0.93
All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J (2015) 0.93
PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length. Mol Cell (2014) 0.92
The role of PP2A A subunits in tumor suppression. Cell Adh Migr (2007) 0.89
Restricted protein phosphatase 2A targeting by Merkel cell polyomavirus small T antigen. J Virol (2015) 0.89
Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk. Cancer (2010) 0.89
PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs: Potential Implications for PP2A Disruption in Cancer. Genes Cancer (2012) 0.87
Comparisons between murine polyomavirus and Simian virus 40 show significant differences in small T antigen function. J Virol (2011) 0.87
B56γ tumor-associated mutations provide new mechanisms for B56γ-PP2A tumor suppressor activity. Mol Cancer Res (2013) 0.85
A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence. Int J Cancer (2011) 0.83
Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas. Proteomics Clin Appl (2008) 0.82
Nitric oxide leads to cytoskeletal reorganization in the retinal pigment epithelium under oxidative stress. Adv Biosci Biotechnol (2012) 0.81
HEAT repeat 1 motif is required for B56γ-containing protein phosphatase 2A (B56γ-PP2A) holoenzyme assembly and tumor-suppressive function. J Biol Chem (2012) 0.81
Identification and functional analysis of variant haplotypes in the 5'-flanking region of protein phosphatase 2A-Bδ gene. PLoS One (2012) 0.81
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia. Front Oncol (2016) 0.80
Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target. Cancer Biol Ther (2013) 0.80
B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability. J Clin Invest (2015) 0.79
Role of a novel functional variant in the PPP2R1A promoter on the regulation of PP2A-Aalpha and the risk of hepatocellular carcinoma. PLoS One (2013) 0.79
Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proc Natl Acad Sci U S A (2015) 0.78
PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling. Cancer Res (2016) 0.78
The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin (2016) 0.77
Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia. Front Oncol (2015) 0.77
Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work? Am J Cancer Res (2015) 0.77
Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells. J Biol Chem (2014) 0.76
NNMT silencing activates tumor suppressor PP2A, inactivates oncogenic STKs and inhibits tumor forming ability. Clin Cancer Res (2016) 0.75
Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway. Sci Rep (2016) 0.75
The PP2A-B56 Phosphatase Opposes Cyclin E Autocatalytic Degradation via Site-Specific Dephosphorylation. Mol Cell Biol (2017) 0.75
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods (2006) 4.12
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene (2002) 3.80
Chemosensitivity linked to p73 function. Cancer Cell (2003) 3.63
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell (2003) 3.33
β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell (2012) 3.33
Telomerase maintains telomere structure in normal human cells. Cell (2003) 3.29
Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell (2004) 3.29
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell (2003) 3.23
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J Virol (2009) 3.16
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature (2009) 3.04
A genetically defined model for human ovarian cancer. Cancer Res (2004) 3.02
Making sense of cancer genomic data. Genes Dev (2011) 3.01
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A (2002) 2.82
Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol (2011) 2.69
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell (2010) 2.68
A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol (2002) 2.66
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet (2012) 2.63
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53
Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med (2008) 2.52
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature (2013) 2.46
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 2.39
T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci U S A (2003) 2.34
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell (2006) 2.15
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell (2009) 2.15
Roots and stems: stem cells in cancer. Nat Med (2006) 2.13
The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell (2007) 2.10
Involvement of PP2A in viral and cellular transformation. Oncogene (2005) 2.07
The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A (2005) 2.01
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell (2009) 2.00
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov (2014) 1.99
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest (2010) 1.98
Cancer vulnerabilities unveiled by genomic loss. Cell (2012) 1.95
An oncogenic role for ETV1 in melanoma. Cancer Res (2010) 1.94
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A (2008) 1.92
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A (2010) 1.91
ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res (2012) 1.86
Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol (2005) 1.81
Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet (2003) 1.78
Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A (2003) 1.73
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet (2012) 1.70
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
Oncogenic transformation and experimental models of human cancer. Front Biosci (2008) 1.59
HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell (2013) 1.58
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov (2011) 1.57
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer (2013) 1.52
Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res (2010) 1.47
Evolving views of telomerase and cancer. Trends Cell Biol (2003) 1.47
Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol (2004) 1.46
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med (2012) 1.42
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res (2004) 1.42
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol (2010) 1.35
SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal (2009) 1.35
SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev (2008) 1.34
The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell (2005) 1.34
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A (2012) 1.34
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A (2013) 1.33